Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including ARDS caused by COVID-19.
Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24. Discuss
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications.
Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3.
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas.
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2.
Carma Cell Therapies said it has expanded the phase I trial of its Mcy-M11 lead anti-mesothelin messenger RNA chimeric antigen receptor- peripheral blood mononuclear cell cell-therapy candidate to include a new parallel cohort of patients and two additional clinical sites.
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.
A new study has demonstrated that "foreign" DNA -- DNA transferred horizontally into a species from a source other than a parent -- can become functional over time and can impact an organism's evolution and fitness, according to a paper published August 10 in Nature Ecology and Evolution. Discuss
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
